Headquartered in Parsippany, NJ Fiscal year ends December NYSE: ZTS zoetis.com
Zoetis Inc. is the world's largest animal health company, focused exclusively on discovering, developing, manufacturing, and commercializing medicines, vaccines, diagnostics, biopharmaceuticals, and digital solutions for companion animals and livestock. With a legacy of nearly 75 years, Zoetis operates in over 100 countries and serves veterinarians, livestock producers, and pet owners. The company organizes its commercial operations into two geographic segments — United States and International — and delivers products across species including dogs, cats, horses, cattle, swine, poultry, fish, and sheep. Key product franchises include Simparica Trio (parasiticide), its dermatology portfolio, Librela and Lenivia/Portela (OA pain), Revolution/Stronghold (parasiticide), and a growing diagnostics business including point-of-care analyzers and teleradiology services. Zoetis also maintains a contract manufacturing and human health business. The company's pipeline includes more than 12 potential blockbuster candidates targeting chronic kidney disease, oncology, cardiology, anxiety, and obesity in animals. Updated
Rescuing a dog or cat can easily turn into a 10- to 20-year financial commitment. Medium-sized dogs often live around 10 to 13 years, while many cats live into their mid-teens and…
Pre-Market Stock Futures: Futures are trading higher as we hit the mid-week point, as the technology-led rally continues to spiral higher. While the major indices finished the day mixed, the technology-heavy Nasdaq…
Morningstar’s Investing Insights podcast recently spotlighted four S&P 500 stocks that have already declared dividend increases of 10% or more, effectively locking in their place on next year’s Dividend Growers screen, which…
On a recent Morningstar Investing Insights segment unveiling the 2026 class of exceptional dividend growers, the host offered one caveat worth the entire show: “Valuation was not a component in this screen…
One of Wall Street’s top firms just gave a thumbs-up to Zoetis (NYSE:ZTS | ZTS Price Prediction) stock. Citi initiated coverage with a Buy rating and a $145 price target, naming it…
Pre-Market Stock Futures: Futures are trading lower as we prepare to finally end what has been one of the most volatile weeks in recent memory, with oil hitting its highest level since…
Pre-Market Stock Futures: Futures are trading higher on Monday as we head into the final trading weeks of 2025. All of the major indices were hit hard on Friday as investors began…
The steep increase in pet healthcare costs have doubled over the past five years, according to NPR. There are a number of reasons for this trend, but the overall numbers are large,…
British billionaire investor Terry Smith is known as “the English Warren Buffett.” His London-based investment management firm, Fundsmith, was founded in 2010 and is known for Smith’s disciplined, long-term approach to investing.…
After years of a low-interest rate environment, which has reversed in a big way over the last 18 months, many investors continue to turn to equities not only for growth potential but…
Thursday's top analyst upgrades and downgrades included American Airlines, Amgen, Block, Chewy, First Solar, Nvidia, Southwest Airlines, Taiwan Semiconductor Manufacturing and Toast.
Friday's top analyst upgrades and downgrades included Arista Networks, DataDog, FedEx, Fiserv, Gilead Sciences, Global Payments, Nvidia, Oatly, Pfizer, Target, TJX Companies and Victoria’s Secret.
Monday's top analyst upgrades and downgrades included Accenture, Coca-Cola, Fastly, First Solar, Lemonade, Marvell Technology, Peloton Interactive and Target.
Goldman Sachs has seven biopharma stocks on its Conviction Buy list, and these are not all coronavirus plays. The firm thinks these stocks could go on the offensive for the rest of…
Tuesday's top analyst upgrades and downgrades included AbbVie, ANGI Homeservices, CBOE, Darden Restaurants, Hess, Lululemon Athletica, MongoDB, PayPal, Shopify, Slack and Zynga.
Zoetis Inc. is the world's largest animal health company, focused exclusively on discovering, developing, manufacturing, and commercializing medicines, vaccines, diagnostics, biopharmaceuticals, and digital solutions for companion animals and livestock.
24/7 Wall St.'s 12-month price target for ZTS is $97.31, rated Buy. The Wall Street consensus target is $94.86. ZTS price prediction →
